Cancer dominates newly revealed list of drugs under evaluation at EMA
This article was originally published in SRA
Executive Summary
A total of 76 medicines for human use are under evaluation at the European Medicines Agency, of which 18 are for cancer indications, five for diabetes and four for respiratory tract diseases, the agency has disclosed as part of its drive for transparency1.
You may also be interested in...
Coronavirus Notebook: Italy Makes First Use Of EU’s Vaccine Export Control System, More Regulators Issue Guidance On Variants
Ukraine has established a system for issuing emergency use authorizations for COVID-19 vaccines that recognizes authorizations granted by other world regulators.
Russia’s Sputnik V COVID-19 Vaccine Starts EU Rolling Review
The Russian backers of the vaccine’s development say that if it receives a marketing authorization in the EU, distribution could begin in June this year.
Coronavirus Notebook: EU Moots Emergency Use Authorization Scheme For Vaccines, Janssen Product Up For 11 March Approval
Celltrion’s regdanvimab is undergoing an emergency use procedure in Europe, the European Medicines Agency and the health authorities in Canada have jointly published clinical data on the Moderna vaccine, and Canada has approved two versions of the AstraZeneca/Oxford University jab.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: